Skin Care Education

Nuceiva

A botulinum toxin type A neuromodulator made by Evolus, approved for the treatment of moderate to severe frown lines and used across a range of aesthetic applications to temporarily relax facial muscles and reduce expression lines.

What Is Nuceiva?

Nuceiva is a brand of botulinum toxin type A made by Evolus. It is sold under the name Jeuveau in the United States and as Nuceiva in Canada and other markets. Like other botulinum toxin type A products, Nuceiva works by temporarily blocking the nerve signals that cause muscles to contract. When injected in precise, small doses into targeted facial muscles, it prevents those muscles from contracting with their normal force, allowing the overlying skin to smooth out and expression lines to become less visible.

Nuceiva is sometimes described as a modern neuromodulator in that it was developed more recently than products such as Botox and Dysport and uses a purification process that Evolus markets as producing a highly purified form of botulinum toxin type A. It is specifically approved for the treatment of moderate to severe glabellar lines, the frown lines between the brows, and is used by clinicians across the same range of aesthetic applications as other neuromodulators.

In practical terms, Nuceiva produces the same type of result as other botulinum toxin type A products: a temporary reduction in muscle activity that softens expression lines and relaxes muscle-related concerns. The choice between Nuceiva and other brands is typically made by the provider based on their clinical experience and preference rather than a meaningful clinical difference in outcome for the patient.

What to Expect

Nuceiva treatment follows the standard process for all neuromodulator injections. A series of small injections are placed precisely into the targeted muscles using a fine needle. The procedure takes 10 to 20 minutes and most people describe the sensation as a mild pinch at each injection site. Numbing cream is not usually needed. There is no significant downtime.

The effect typically begins to appear within two to five days and is fully established at two weeks. A review appointment at two weeks is standard practice to assess the result. The effect lasts approximately three to four months, after which muscle activity gradually returns to normal and retreatment maintains the result.

Standard aftercare applies: avoiding vigorous exercise, excessive heat, and pressure on the treated areas for the first 24 hours after treatment. No rubbing or massaging of the injection sites during this period.

Who It’s For and Results

Nuceiva is suited to the same range of candidates as other neuromodulator treatments: adults who want to reduce the visibility of expression lines, prevent their deepening, or address other muscle-related concerns including jaw slimming, brow lifting, neck band relaxation, and excessive sweating.

Results are a natural-looking softening of treated expression lines with preservation of normal facial movement. As with all neuromodulators, the quality of the result depends primarily on the skill and experience of the provider, the appropriateness of the dosing, and the precision of placement rather than which specific brand is used.

Regular maintenance treatments every three to four months sustain the result. Many people find with consistent treatment over time that their results progressively last a little longer as the treated muscles reduce slightly in bulk.

Frequently Asked Questions: Nuceiva

Both Nuceiva and Botox contain botulinum toxin type A and work through the same mechanism to temporarily relax facial muscles and reduce expression lines. Nuceiva is made by Evolus and markets itself as a highly purified formulation. Botox is made by Allergan and has a much longer track record and broader clinical research base. In clinical practice, both produce comparable aesthetic results when used by an experienced provider familiar with the product. The choice between them is usually a provider preference rather than a clinically meaningful difference from the patient’s perspective.

Yes. Nuceiva and Jeuveau are the same product, botulinum toxin type A made by Evolus, sold under different brand names in different markets. Jeuveau is the name used in the United States and Nuceiva is used in Canada and other markets. The formulation and clinical application are identical. If someone encounters both names, they refer to the same injectable neuromodulator treatment.

Nuceiva typically lasts three to four months, comparable to other botulinum toxin type A products. Individual variation means some people experience results lasting closer to three months and others closer to five. Factors that influence duration include the amount used, the individual’s metabolism and muscle activity, and the area treated. Regular retreatment before the effect fully wears off maintains a consistent result over time.

Yes. Switching between neuromodulator brands is straightforward as all botulinum toxin type A products work through the same mechanism. A provider switching a client from one brand to another will adjust the dosing as needed, as the unit systems between brands are not directly equivalent. There is no clinical reason why a good response to Botox or Dysport would not translate to a similar response to Nuceiva, and vice versa. Many providers have a preferred brand they use consistently, while others select between products based on availability or specific treatment considerations.